Global Consultation on Cancer Staging: promoting consistent understanding and use

James Brierley, Brian O’Sullivan, Hisao Asamura, David Byrd, Shao Hui Huang, Anne Lee, Marion Piñeros, Malcolm Mason, Fabio Y. Moraes, Wiebke Rösler, Brian Rous, Julie Torode, J. Han van Krieken, Mary Gospodarowicz

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Disease burden is the most important determinant of survival in patients with cancer. This domain, reflected by the cancer stage and codified using the tumour-node-metastasis (TNM) classification, is a fundamental determinant of prognosis. Accurate and consistent tumour classification is required for the development and use of treatment guidelines and to enable clinical research (including clinical trials), cancer surveillance and control. Furthermore, knowledge of the extent and stage of disease is frequently important in the context of translational studies. Attempts to include additional prognostic factors in staging classifications, in order to facilitate a more accurate determination of prognosis, are often made with a lack of knowledge and understanding and are one of the main causes of the inconsistent use of terms and definitions. This effect has resulted in uncertainty and confusion, thus limiting the utility of the TNM classification. In this Position paper, we provide a consensus on the optimal use and terminology for cancer staging that emerged from a consultation process involving representatives of several major international organizations involved in cancer classification. The consultation involved several steps: a focused literature review; a stakeholder survey; and a consultation meeting. This aim of this Position paper is to provide a consensus that should guide the use of staging terminology and secure the classification of anatomical disease extent as a distinct aspect of cancer classification.

Original languageEnglish
JournalNature Reviews Clinical Oncology
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Neoplasm Staging
Referral and Consultation
Neoplasms
Terminology
Neoplasm Metastasis
Uncertainty
Clinical Trials
Guidelines
Survival
Research

ASJC Scopus subject areas

  • Oncology

Cite this

Brierley, J., O’Sullivan, B., Asamura, H., Byrd, D., Huang, S. H., Lee, A., ... Gospodarowicz, M. (Accepted/In press). Global Consultation on Cancer Staging: promoting consistent understanding and use. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-019-0253-x

Global Consultation on Cancer Staging : promoting consistent understanding and use. / Brierley, James; O’Sullivan, Brian; Asamura, Hisao; Byrd, David; Huang, Shao Hui; Lee, Anne; Piñeros, Marion; Mason, Malcolm; Moraes, Fabio Y.; Rösler, Wiebke; Rous, Brian; Torode, Julie; van Krieken, J. Han; Gospodarowicz, Mary.

In: Nature Reviews Clinical Oncology, 01.01.2019.

Research output: Contribution to journalReview article

Brierley, J, O’Sullivan, B, Asamura, H, Byrd, D, Huang, SH, Lee, A, Piñeros, M, Mason, M, Moraes, FY, Rösler, W, Rous, B, Torode, J, van Krieken, JH & Gospodarowicz, M 2019, 'Global Consultation on Cancer Staging: promoting consistent understanding and use', Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-019-0253-x
Brierley, James ; O’Sullivan, Brian ; Asamura, Hisao ; Byrd, David ; Huang, Shao Hui ; Lee, Anne ; Piñeros, Marion ; Mason, Malcolm ; Moraes, Fabio Y. ; Rösler, Wiebke ; Rous, Brian ; Torode, Julie ; van Krieken, J. Han ; Gospodarowicz, Mary. / Global Consultation on Cancer Staging : promoting consistent understanding and use. In: Nature Reviews Clinical Oncology. 2019.
@article{48328ab5fd5144fe9c1a6d572289277b,
title = "Global Consultation on Cancer Staging: promoting consistent understanding and use",
abstract = "Disease burden is the most important determinant of survival in patients with cancer. This domain, reflected by the cancer stage and codified using the tumour-node-metastasis (TNM) classification, is a fundamental determinant of prognosis. Accurate and consistent tumour classification is required for the development and use of treatment guidelines and to enable clinical research (including clinical trials), cancer surveillance and control. Furthermore, knowledge of the extent and stage of disease is frequently important in the context of translational studies. Attempts to include additional prognostic factors in staging classifications, in order to facilitate a more accurate determination of prognosis, are often made with a lack of knowledge and understanding and are one of the main causes of the inconsistent use of terms and definitions. This effect has resulted in uncertainty and confusion, thus limiting the utility of the TNM classification. In this Position paper, we provide a consensus on the optimal use and terminology for cancer staging that emerged from a consultation process involving representatives of several major international organizations involved in cancer classification. The consultation involved several steps: a focused literature review; a stakeholder survey; and a consultation meeting. This aim of this Position paper is to provide a consensus that should guide the use of staging terminology and secure the classification of anatomical disease extent as a distinct aspect of cancer classification.",
author = "James Brierley and Brian O’Sullivan and Hisao Asamura and David Byrd and Huang, {Shao Hui} and Anne Lee and Marion Pi{\~n}eros and Malcolm Mason and Moraes, {Fabio Y.} and Wiebke R{\"o}sler and Brian Rous and Julie Torode and {van Krieken}, {J. Han} and Mary Gospodarowicz",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41571-019-0253-x",
language = "English",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Global Consultation on Cancer Staging

T2 - promoting consistent understanding and use

AU - Brierley, James

AU - O’Sullivan, Brian

AU - Asamura, Hisao

AU - Byrd, David

AU - Huang, Shao Hui

AU - Lee, Anne

AU - Piñeros, Marion

AU - Mason, Malcolm

AU - Moraes, Fabio Y.

AU - Rösler, Wiebke

AU - Rous, Brian

AU - Torode, Julie

AU - van Krieken, J. Han

AU - Gospodarowicz, Mary

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Disease burden is the most important determinant of survival in patients with cancer. This domain, reflected by the cancer stage and codified using the tumour-node-metastasis (TNM) classification, is a fundamental determinant of prognosis. Accurate and consistent tumour classification is required for the development and use of treatment guidelines and to enable clinical research (including clinical trials), cancer surveillance and control. Furthermore, knowledge of the extent and stage of disease is frequently important in the context of translational studies. Attempts to include additional prognostic factors in staging classifications, in order to facilitate a more accurate determination of prognosis, are often made with a lack of knowledge and understanding and are one of the main causes of the inconsistent use of terms and definitions. This effect has resulted in uncertainty and confusion, thus limiting the utility of the TNM classification. In this Position paper, we provide a consensus on the optimal use and terminology for cancer staging that emerged from a consultation process involving representatives of several major international organizations involved in cancer classification. The consultation involved several steps: a focused literature review; a stakeholder survey; and a consultation meeting. This aim of this Position paper is to provide a consensus that should guide the use of staging terminology and secure the classification of anatomical disease extent as a distinct aspect of cancer classification.

AB - Disease burden is the most important determinant of survival in patients with cancer. This domain, reflected by the cancer stage and codified using the tumour-node-metastasis (TNM) classification, is a fundamental determinant of prognosis. Accurate and consistent tumour classification is required for the development and use of treatment guidelines and to enable clinical research (including clinical trials), cancer surveillance and control. Furthermore, knowledge of the extent and stage of disease is frequently important in the context of translational studies. Attempts to include additional prognostic factors in staging classifications, in order to facilitate a more accurate determination of prognosis, are often made with a lack of knowledge and understanding and are one of the main causes of the inconsistent use of terms and definitions. This effect has resulted in uncertainty and confusion, thus limiting the utility of the TNM classification. In this Position paper, we provide a consensus on the optimal use and terminology for cancer staging that emerged from a consultation process involving representatives of several major international organizations involved in cancer classification. The consultation involved several steps: a focused literature review; a stakeholder survey; and a consultation meeting. This aim of this Position paper is to provide a consensus that should guide the use of staging terminology and secure the classification of anatomical disease extent as a distinct aspect of cancer classification.

UR - http://www.scopus.com/inward/record.url?scp=85070416981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070416981&partnerID=8YFLogxK

U2 - 10.1038/s41571-019-0253-x

DO - 10.1038/s41571-019-0253-x

M3 - Review article

AN - SCOPUS:85070416981

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -